NASDAQ:RNAC - Nasdaq - US8162123025 - Common Stock - Currency: USD
9.34
-0.2 (-2.1%)
The current stock price of RNAC is 9.34 USD. In the past month the price decreased by -7.98%. In the past year, price decreased by -74.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.25 | 331.15B | ||
AMGN | AMGEN INC | 13.83 | 154.38B | ||
GILD | GILEAD SCIENCES INC | 14.27 | 137.40B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.97B | ||
REGN | REGENERON PHARMACEUTICALS | 10.9 | 52.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.16B | ||
ARGX | ARGENX SE - ADR | 100.97 | 35.45B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.57 | 27.78B | ||
BNTX | BIONTECH SE-ADR | N/A | 26.48B | ||
NTRA | NATERA INC | N/A | 22.60B | ||
BIIB | BIOGEN INC | 8.24 | 19.10B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 14.65B |
Cartesian Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Frederick, Maryland and currently employs 66 full-time employees. The company went IPO on 2016-06-22. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function. The Company’s lead asset, Descartes-08, is a chimeric antigen receptor T-cell therapy (CAR-T) entering Phase 3 clinical development for patients with generalized myasthenia gravis and Phase 2 development for systemic lupus erythematosus, with a Phase 2 basket trial planned in additional autoimmune indications. The Company’s clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-B-cell maturation antigen (BCMA) CAR-T being evaluated in a Phase 1 trial in patients with multiple myeloma. Descartes-08 is an autologous chimeric antigen receptor T-cell therapy product targeting B-cell maturation antigen in clinical development for generalized myasthenia gravis and systemic lupus erythematosus.
CARTESIAN THERAPEUTICS INC
7495 New Horizon Way
Frederick MARYLAND US
Employees: 66
Phone: 13013488698
The current stock price of RNAC is 9.34 USD. The price decreased by -2.1% in the last trading session.
The exchange symbol of CARTESIAN THERAPEUTICS INC is RNAC and it is listed on the Nasdaq exchange.
RNAC stock is listed on the Nasdaq exchange.
14 analysts have analysed RNAC and the average price target is 39.95 USD. This implies a price increase of 327.73% is expected in the next year compared to the current price of 9.34. Check the CARTESIAN THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
CARTESIAN THERAPEUTICS INC (RNAC) has a market capitalization of 242.37M USD. This makes RNAC a Micro Cap stock.
CARTESIAN THERAPEUTICS INC (RNAC) currently has 66 employees.
CARTESIAN THERAPEUTICS INC (RNAC) has a resistance level at 9.45. Check the full technical report for a detailed analysis of RNAC support and resistance levels.
The Revenue of CARTESIAN THERAPEUTICS INC (RNAC) is expected to decline by -91.16% in the next year. Check the estimates tab for more information on the RNAC EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
RNAC does not pay a dividend.
CARTESIAN THERAPEUTICS INC (RNAC) will report earnings on 2025-08-06.
CARTESIAN THERAPEUTICS INC (RNAC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.86).
The outstanding short interest for CARTESIAN THERAPEUTICS INC (RNAC) is 43.21% of its float. Check the ownership tab for more information on the RNAC short interest.
ChartMill assigns a fundamental rating of 3 / 10 to RNAC. RNAC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months RNAC reported a non-GAAP Earnings per Share(EPS) of -1.86. The EPS increased by 88.73% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -10.39% | ||
ROE | N/A | ||
Debt/Equity | N/A |
ChartMill assigns a Buy % Consensus number of 81% to RNAC. The Buy consensus is the average rating of analysts ratings from 14 analysts.
For the next year, analysts expect an EPS growth of 71.92% and a revenue growth -91.16% for RNAC